Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study

What Was Tested

The paper reports a study of Romiplostim, published as a randomized controlled trial.

The researchers evaluated the safety and potential effects of early romiplostim administration on platelet and hematopoietic recovery following pediatric HSCT.

Who Took Part

The age groups tagged for this paper are infants, young children, children and teenagers, both men and women.

In this prospective, open-label, randomized pilot study conducted at a tertiary care center in India, children aged 1-18 years undergoing autologous or allogeneic HSCT were randomized (1:1) to receive standard post-transplant care with or without romiplostim.

The primary endpoint was time to platelet engraftment (platelet count ≥20 × 109/L for 3 consecutive days without transfusion).

How the Study Was Run

In design terms this was a randomized, open-label and pilot study.

The participants were allocated by chance, so the Romiplostim group and the comparison group should start out alike.

Everyone knew when Romiplostim was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It is described as a pilot, a small early test of whether a larger Romiplostim study would be practical.

Secondary endpoints included platelet transfusion requirements, platelet nadir, platelet counts on Day +28, time to platelet count ≥50 × 109/L, neutrophil recovery, bleeding, and thrombotic events.

What Was Measured

The researchers evaluated the safety and potential effects of early romiplostim administration on platelet and hematopoietic recovery following pediatric HSCT.

Topics PubMed links to this paper include Thrombopoietin, Pilot Projects, Recombinant Fusion Proteins, Hematopoietic Stem Cell Transplantation, Receptors, Fc, Thrombocytopenia and Hematopoiesis.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Romiplostim.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Pediatric blood & cancer), a journal based in United States.

More context: the Romiplostim compound page, all human trials.